1. Home
  2. AVX vs ELOX Comparison

AVX vs ELOX Comparison

Compare AVX & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVX

Avax One Technology Ltd.

N/A

Current Price

$5.57

Market Cap

47.2M

Sector

Industrials

ML Signal

N/A

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

N/A

Current Price

$0.00

Market Cap

43.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AVX
ELOX
Founded
2017
N/A
Country
Canada
United States
Employees
7
7
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
47.2M
43.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AVX
ELOX
Price
$5.57
N/A
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
277.4K
N/A
Earning Date
05-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
N/A
52 Week High
$6.25
N/A

Technical Indicators

Market Signals
Indicator
AVX
ELOX
Relative Strength Index (RSI) 91.85 N/A
Support Level $0.50 N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.24 0.00
MACD 0.63 0.00
Stochastic Oscillator 88.55 0.00

Price Performance

Historical Comparison
AVX
ELOX

About AVX Avax One Technology Ltd.

AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Share on Social Networks: